Talluri Ravi S, Gaudana Ripal, Hariharan Sudharshan, Mitra Ashim K
Drug Metabolism and Pharmacokinetics, Sai Advantium Pharma Ltd, Pune, India, 411057.
Ophthalmol Eye Dis. 2009 Oct 21;1:21-31. doi: 10.4137/oed.s2857. Print 2009.
To delineate the plasma pharmacokinetics and determine the corneal uptake of valine based stereoisomeric dipeptide prodrugs of acyclovir (ACV) in rats.
Male Sprague-Dawley rats were used for the study. Pharmacokinetics of ACV, L-valine-acyclovir (LACV), L-valine-D-valine-acyclovir (LDACV) and D-valine-L-valine acyclovir (DLACV) prodrugs were delineated. These compounds were administered intravenously as a bolus via jugular vein cannula and orally by gavage. Samples were purified by protein precipitation method and analyzed by LC-MS/MS. Pertinent pharmacokinetic parameters were obtained by using WinNonlin. Corneal uptake studies of LDACV and LACV were studied following oral administration.
Following i.v. administration, the area under the curve (AUC) in μMmin of generated ACV was in the order of LACV > LDACV > DLACV indicating their rate of metabolism. The AUC values of total drug obtained in the systemic circulation after oral administration LACV and LDACV were 1077.93 ± 236.09 and 1141.76 ± 73.67 μMmin, respectively. DLACV exhibited poor oral absorption. Cmax (μM) and AUC of the intact prodrug obtained in the systemic circulation following oral administration of LDACV were almost 4-5 times higher than LACV. Moreover, concentrations achieved in the cornea after oral administration of LDACV were almost two times of LACV.
LDACV increased both the oral bioavailability and subsequent in vivo corneal uptake of ACV. Hence, LDACV can be considered as the most promising drug candidate for delivery of ACV, in treatment of both genital herpes and ocular herpes keratitis after oral administration.
描述缬氨酸基阿昔洛韦(ACV)立体异构二肽前药在大鼠体内的血浆药代动力学,并测定其角膜摄取情况。
选用雄性Sprague-Dawley大鼠进行研究。描绘了ACV、L-缬氨酸-阿昔洛韦(LACV)、L-缬氨酸-D-缬氨酸-阿昔洛韦(LDACV)和D-缬氨酸-L-缬氨酸阿昔洛韦(DLACV)前药的药代动力学。这些化合物通过颈静脉插管静脉推注给药,并通过灌胃口服给药。样品采用蛋白沉淀法纯化,并用LC-MS/MS分析。使用WinNonlin获得相关药代动力学参数。口服给药后研究了LDACV和LACV的角膜摄取情况。
静脉给药后,生成的ACV的曲线下面积(AUC,单位为μMmin)顺序为LACV > LDACV > DLACV,表明它们的代谢速率。口服LACV和LDACV后在体循环中获得的总药物AUC值分别为1077.93±236.09和1141.76±73.67μMmin。DLACV口服吸收较差。口服LDACV后在体循环中获得的完整前药的Cmax(μM)和AUC比LACV高近4-5倍。此外,口服LDACV后角膜中的浓度几乎是LACV的两倍。
LDACV提高了ACV的口服生物利用度以及随后在体内的角膜摄取。因此,LDACV可被视为口服给药治疗生殖器疱疹和眼部疱疹性角膜炎时最有前景的ACV给药候选药物。